Equity Research Medical Devices

Should You Buy Pulsenmore Ltd. Stock in 2026?

By CirclFi Research Team · · Updated · 2/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Pulsenmore Ltd. (PLSM) occupies a solid middle-ground position with a Quality of Company score of 5.6/10. At the current market price of $2.41, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.

The short answer: 2 of 2 CirclFi valuation models project upside for Pulsenmore Ltd. (PLSM) at $2.41 — the model consensus leans bullish, with a Quality Score of 5.6/10 and Value-Trap risk of 10/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 2 of 2 models see upside — majority bullish
  • Quality Score: 5.6/10 — Moderate — mixed signals
  • Value Trap Risk: 10/100 — Minimal — healthy fundamentals
  • Fair Value Range: $2.70 – $7.37 (173% spread)

Bullish Models

2 / 2

Bearish Models

0 / 2

Quality Score

5.6 /10

Moderate — mixed signals

Value Trap Risk

10 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

2 /13
Active Models

Avg. confidence: 23%

What Is the Investment Case for Pulsenmore Ltd. (PLSM) in 2026?

What Is the Bull Case vs the Bear Case for Pulsenmore Ltd. (PLSM)?

Bull case versus bear case for Pulsenmore Ltd. (PLSM) at $2.41, derived from 2 active CirclFi valuation models on 2026-09-15.
Bull case — $7.37 target (+205.9%) Bear case
According to the CirclFi Deep Alpha Valuation Engine, the stock shows multi-model upside with a median implied return of +109.0% across 2 bullish models from the current price of $2.41. No active model flags significant downside for PLSM. The low Value Trap score paints a constructive picture.
According to the CirclFi Deep Alpha Valuation Engine, the FTNN Topology model targets a fair value of $7.37 (+205.9%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
Industry tailwind: licensing and M&A optionality could provide meaningful support for Pulsenmore Ltd.'s revenue and margin trajectory in the Medical Devices space.

How Does PLSM Compare to Its Medical Devices Peers?

BMRA Biomerica, Inc.
5.6
NXL Nexalin Technology,
5.6
NNOX Nano-X Imaging Ltd.
5.6
LUCD Lucid Diagnostics In
5.5
NYXH Nyxoah SA
5.6
GTHP Guided Therapeutics,
5.5
ODYY Odyssey Health, Inc.
3.7
BIO Bio-Rad Laboratories
7.8

Valuation data pages: BMRA · NXL · NNOX · LUCD · NYXH · GTHP · ODYY · BIO · RXST · IRMD · PODD

See full Medical Devices rankings →

Which Other Stocks Score Like PLSM on Quality?

Closest companies to PLSM’s Quality of Company score of 5.6/10, across all industries.

Why Do CirclFi’s 2 Models Disagree on PLSM?

Spread

173%

Fair Value Range

$2.70 – $7.37

A 173% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

FTNN

$7.37 (+205.9%)

Most Bearish

Dynamic NAV

$2.70 (+12.0%)

What Are the Biggest Risks of Buying PLSM Stock?

Model Disagreement

173% spread signals high variance in projections.

Macro/Sector Risk

Medical Devices headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View PLSM Data Page →

So Is Pulsenmore Ltd. (PLSM) Worth Buying in 2026?

The convergence of 5.6/10 quality, multi-model undervaluation (2/2 bullish, +109.0% median upside), and a median fair value of $5.04 vs. $2.41 current price makes Pulsenmore Ltd. one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.

These are quantitative model outputs, not investment recommendations. Pulsenmore Ltd.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About PLSM Stock?

Should I buy PLSM stock right now?

Based on CirclFi's multi-model analysis, 2 of 2 models see upside for PLSM at $2.41. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 5.6/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Pulsenmore Ltd.?

Key risks include: limited model coverage (2/13 active), reducing analytical confidence; wide model disagreement (173% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.

How does PLSM compare to its competitors?

Among Medical Devices peers, PLSM holds a Quality Score of 5.6/10. Comparable companies include BMRA (QOC 5.6), NXL (QOC 5.6), NNOX (QOC 5.6). The relative ranking helps investors identify whether PLSM offers better fundamental quality than alternatives in the same sector.

Is PLSM a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. PLSM's Quality Score of 5.6/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy PLSM at?

CirclFi does not provide target buy prices or price alerts. However, our 2 active models produce fair value estimates ranging from $2.70 to $7.37. At $2.41, the stock trades below even the most conservative estimate, which may represent a margin of safety — or reflect risks the models don't capture. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for PLSM.

View PLSM Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →